Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NUC-B: Nucleos(t)ide withdrawal in HBeAg-negative chronic hepatitis B
2016-001010-17Phase 2Unknown
- Sponsor
- Imperial College London
- Start
- Jul 2016
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of interferon alfa in Chronic Hepatitis B (CHB) (2 arms), sponsored by Imperial College London. Primary endpoint: HBsAg loss at 3 years. Status: unknown.
02
Drugs
interferon alfa
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2016-001010-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001010-17.